BenzingaSeptember 23, 2026 at 5:20 AM NYLast Month
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
